Human hepatocyte--a model for toxicological studies. Functional and biochemical characterization

Current toxicological research often relies on in vitro models to predict human liver responses to drugs and toxins. While animal hepatocytes have been used traditionally, human hepatocytes (HH) are increasingly preferred for studies involving human-specific biotransformation processes. Prior research has shown that HH can maintain metabolic activity for several days in culture, but variability in donor characteristics can affect cell performance. This gap motivated the current investigation into optimizing HH isolation and culture conditions. No prior work had resolved how clinical liver test parameters correlate with HH functionality in culture. Establishing standardized protocols remains a challenge due to donor variability. The need for reliable in vitro models is especially high in drug development and safety testing. This study aims to address these uncertainties by evaluating how donor health markers influence HH quality. Understanding these factors could improve the reproducibility of toxicological experiments.

The study aimed to assess the suitability of isolated human hepatocytes for toxicological experiments by optimizing isolation and culture conditions. Researchers focused on cell viability, metabolic activity, and response to toxins and cytoprotective agents. The motivation stemmed from the need to ensure that in vitro models accurately reflect human liver function. Donor variability was a central concern, as it could affect experimental outcomes. The study evaluated clinical liver tests as indicators of hepatocyte quality in culture. By measuring cytochrome P450 levels and enzyme activities, the team sought to establish reliable protocols. The goal was to determine how donor health parameters influence cell functionality. This approach could help standardize toxicological testing using human hepatocytes.

The study used primary cultures of human hepatocytes obtained from five multiorgan donors. Researchers measured cell viability, cytochrome P450 content, and specific enzyme activities like CYP3A4 and ECOD. They assessed culture quality by monitoring lactate dehydrogenase leakage and responses to tert-butylhydroperoxide and silybinin. Donor samples were evaluated for a seven-day period following a 24-hour stabilization phase. Clinical liver tests, including aminotransferase and bilirubin levels, were recorded for each donor. The team compared these parameters to determine their influence on hepatocyte function. Statistical analysis was used to identify correlations between donor health and cell performance. These methods aimed to establish a reliable framework for toxicological testing.

The study found that donor variability significantly influenced hepatocyte functionality in culture. One donor sample showed increased sensitivity to toxins and silybinin, with higher aminotransferase activity. Another sample demonstrated a link between elevated serum bilirubin and increased ECOD activity. Cell viability and metabolic activity remained stable for seven days after stabilization. Lactate dehydrogenase leakage was used to assess culture quality and toxin response. The average donor age was 44.8 years, with three males and two females. CYP3A4 and CYP1A2 activities varied across donor samples. The highest ECOD activity was observed in the donor with elevated bilirubin levels. These findings suggest that clinical liver tests can predict hepatocyte performance in culture.

The study concluded that clinical liver test results should indicate a healthy organ to ensure stable and functional hepatocyte cultures. Donor variability must be considered when evaluating hepatocyte quality for toxicological experiments. The authors suggest that prior hepatocyte damage is a crucial factor affecting culture stability. No prior work had resolved how clinical markers correlate with in vitro performance. The findings support the use of liver tests as indicators of hepatocyte suitability. The study highlights the importance of selecting donors with normal liver function. Researchers propose that standardized protocols should include clinical assessments. These conclusions align with the observed correlations between bilirubin and ECOD activity.